{"id":"pegylated-liposomal-doxorubicin-hydrochloride","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Palmar-plantar erythrodysesthesia (hand-foot syndrome)"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"15-30","effect":"Stomatitis"},{"rate":"30-50","effect":"Myelosuppression (neutropenia)"},{"rate":"10-20","effect":"Alopecia"},{"rate":"5-10","effect":"Cardiotoxicity"},{"rate":"5-15","effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL359744","moleculeType":"Small molecule","molecularWeight":"579.99"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxorubicin is a topoisomerase II inhibitor and DNA intercalating agent that generates reactive oxygen species and causes DNA damage, leading to apoptosis in cancer cells. The pegylated liposomal formulation encapsulates doxorubicin to extend its half-life, reduce systemic exposure to healthy tissues (particularly the heart), and preferentially accumulate in tumors through the enhanced permeability and retention (EPR) effect, thereby improving the therapeutic index.","oneSentence":"Pegylated liposomal doxorubicin delivers the chemotherapy agent doxorubicin encapsulated in liposomes coated with polyethylene glycol, which intercalates into DNA and inhibits topoisomerase II while reducing cardiotoxicity through prolonged circulation and selective tumor accumulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:18.967Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic ovarian cancer"},{"name":"AIDS-related Kaposi sarcoma"},{"name":"Multiple myeloma (in combination with bortezomib)"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT06072781","phase":"PHASE3","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2024-03-18","conditions":"Low Grade Serous Ovarian Cancer","enrollment":270},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":"Ovarian Cancer","enrollment":358},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT06345950","phase":"NA","title":"Pharmacokinetics and Safety of a New Micellar Glutathione Formulation","status":"COMPLETED","sponsor":"Factors Group of Nutritional Companies Inc.","startDate":"2022-06-21","conditions":"Bioavailability Heathy Volunteers, Safety","enrollment":16},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT05411237","phase":"PHASE3","title":"Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2026-09","conditions":"Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma","enrollment":130},{"nctId":"NCT06981637","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-12-31","conditions":"Advanced Soft Tissue Sarcoma","enrollment":81},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT06161025","phase":"PHASE2, PHASE3","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-27","conditions":"Solid Cancer","enrollment":860},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT05483933","phase":"PHASE1","title":"Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers","status":"COMPLETED","sponsor":"Shattuck Labs, Inc.","startDate":"2022-08-18","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT07286240","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-11-15","conditions":"Treatment of Recurrent Ovarian Cancer","enrollment":40},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":"Lymphoma, Large B-Cell, Diffuse Large B-Cell","enrollment":127},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT05029999","phase":"PHASE1","title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-04-20","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT06023862","phase":"PHASE2","title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-01-22","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms","enrollment":198},{"nctId":"NCT04575961","phase":"PHASE2","title":"Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2022-02-22","conditions":"Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma","enrollment":33},{"nctId":"NCT06014528","phase":"PHASE2","title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-09-06","conditions":"Ovarian Cancer Recurrent","enrollment":168},{"nctId":"NCT04274426","phase":"PHASE2","title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AGO Research GmbH","startDate":"2021-10-13","conditions":"Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma","enrollment":136},{"nctId":"NCT03353831","phase":"PHASE3","title":"Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer","status":"COMPLETED","sponsor":"AGO Research GmbH","startDate":"2018-09-11","conditions":"Recurrent Ovarian Carcinoma","enrollment":574},{"nctId":"NCT02641639","phase":"PHASE2, PHASE3","title":"FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Mateon Therapeutics","startDate":"2016-06","conditions":"Platinum Resistant Ovarian Cancer","enrollment":70},{"nctId":"NCT06791460","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2025-03-18","conditions":"Ovarian Cancer Recurrent","enrollment":296},{"nctId":"NCT02098343","phase":"PHASE1, PHASE2","title":"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2014-03","conditions":"Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53","enrollment":247},{"nctId":"NCT03268382","phase":"PHASE2","title":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2017-07-31","conditions":"High-grade Serous Ovarian Cancer","enrollment":36},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT01314105","phase":"PHASE1","title":"BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03-15","conditions":"Ovarian Neoplasms, Peritoneal Neoplasms","enrollment":19},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT00170573","phase":"PHASE2","title":"Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2001-09","conditions":"Ovarian Cancer","enrollment":77},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT04516447","phase":"PHASE1","title":"A Study of ZN-c3 in Patients With Ovarian Cancer","status":"RECRUITING","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","startDate":"2020-10-26","conditions":"Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":140},{"nctId":"NCT05261490","phase":"PHASE1, PHASE2","title":"Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma","enrollment":10},{"nctId":"NCT06694324","phase":"PHASE2","title":"First-line Treatment of Advanced/unresectable DDLPS","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)","enrollment":49},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT06653972","phase":"PHASE2","title":"Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wang Jiayu","startDate":"2024-11-01","conditions":"Her2-negative Metastatic Breast Cancer, Vinorelbine, Liposomal Doxorubicin","enrollment":30},{"nctId":"NCT03596281","phase":"PHASE1","title":"Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-12-05","conditions":"Ovarian Cancer","enrollment":47},{"nctId":"NCT03164993","phase":"PHASE2","title":"Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-06-01","conditions":"Cancer, Breast, Triple Negative Breast Cancer","enrollment":68},{"nctId":"NCT03409198","phase":"PHASE2","title":"Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-01-21","conditions":"Breast Cancer, Hormone Receptor Positive Tumor, Metastatic Breast Cancer","enrollment":82},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT01696032","phase":"PHASE2","title":"SGI-110 in Combination With Carboplatin in Ovarian Cancer","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT02606305","phase":"PHASE1, PHASE2","title":"Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"ImmunoGen, Inc.","startDate":"2016-03-02","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":264},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT03719326","phase":"PHASE1","title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","status":"COMPLETED","sponsor":"Arcus Biosciences, Inc.","startDate":"2018-10-15","conditions":"TNBC - Triple-Negative Breast Cancer, Ovarian Cancer","enrollment":35},{"nctId":"NCT01279291","phase":"PHASE1","title":"Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer","status":"TERMINATED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-01","conditions":"Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms","enrollment":22},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT00712881","phase":"PHASE2","title":"Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Cephalon, Inc.","startDate":"2008-10-13","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT04814875","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy","status":"TERMINATED","sponsor":"THERAPIM PTY LTD","startDate":"2021-09-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":16},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT03907969","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-10-09","conditions":"Advanced Malignancies","enrollment":30},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT04244552","phase":"PHASE1","title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","status":"TERMINATED","sponsor":"Atreca, Inc.","startDate":"2020-02-11","conditions":"Breast Cancer, Colorectal Cancer, Ovarian Cancer","enrollment":87},{"nctId":"NCT04877275","phase":"PHASE2","title":"ATG-010(Selinexor) in Combination With Chemotherapy in RRMM","status":"UNKNOWN","sponsor":"Chunyan Sun, MD","startDate":"2021-05-21","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01990352","phase":"PHASE2","title":"Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2013-11-05","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT01177683","phase":"PHASE1, PHASE2","title":"Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma","status":"TERMINATED","sponsor":"Sherif Farag, MB, BS","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT02272790","phase":"PHASE2","title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-30","conditions":"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation","enrollment":95},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT05201001","phase":"PHASE2","title":"APX005M in Patients With Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2023-09-07","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT05976932","phase":"","title":"Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-08","conditions":"Ovarian Cancer","enrollment":20},{"nctId":"NCT02580058","phase":"PHASE3","title":"A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12-21","conditions":"Ovarian Cancer","enrollment":566},{"nctId":"NCT00003388","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-07-26","conditions":"Lymphoma","enrollment":38},{"nctId":"NCT00258960","phase":"PHASE2","title":"Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2006-02-15","conditions":"Breast Cancer","enrollment":49},{"nctId":"NCT02315196","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":62},{"nctId":"NCT05255471","phase":"PHASE3","title":"MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2022-01-21","conditions":"Ovarian Cancer","enrollment":200},{"nctId":"NCT01802749","phase":"PHASE3","title":"Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2013-11","conditions":"Recurrent Ovarian Cancer","enrollment":406},{"nctId":"NCT05774275","phase":"PHASE1, PHASE2","title":"The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-08-25","conditions":"High-Risk Localized Soft Tissue Sarcoma","enrollment":52},{"nctId":"NCT05536102","phase":"PHASE2","title":"The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-09-05","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT00128778","phase":"PHASE4","title":"Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2002-10-28","conditions":"Breast Neoplasms","enrollment":288},{"nctId":"NCT05386524","phase":"PHASE2","title":"Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-15","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT05731258","phase":"","title":"Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Liposomal Doxorubicin, Efficacy","enrollment":150},{"nctId":"NCT03639246","phase":"PHASE1","title":"Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Aravive, Inc.","startDate":"2018-12-06","conditions":"Ovarian Cancer","enrollment":53}],"_emaApprovals":[],"_faersSignals":[{"count":41,"reaction":"ALOPECIA"},{"count":40,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":29,"reaction":"HAIR DISORDER"},{"count":29,"reaction":"HAIR TEXTURE ABNORMAL"},{"count":28,"reaction":"HAIR COLOUR CHANGES"},{"count":25,"reaction":"MADAROSIS"},{"count":25,"reaction":"OFF LABEL USE"},{"count":21,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":21,"reaction":"ARTHROPATHY"},{"count":21,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"}],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Caelyx","Doxil","liposomal doxorubicin","doxorubicin hydrochloride","liposomal doxorubicin hydrochloride"],"phase":"marketed","status":"active","brandName":"Pegylated liposomal doxorubicin hydrochloride","genericName":"Pegylated liposomal doxorubicin hydrochloride","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated liposomal doxorubicin delivers the chemotherapy agent doxorubicin encapsulated in liposomes coated with polyethylene glycol, which intercalates into DNA and inhibits topoisomerase II while reducing cardiotoxicity through prolonged circulation and selective tumor accumulation. Used for Metastatic ovarian cancer, AIDS-related Kaposi sarcoma, Multiple myeloma (in combination with bortezomib).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}